Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells $185,145.00 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Jazz Pharmaceuticals Stock Down 1.9 %

Jazz Pharmaceuticals stock opened at $120.23 on Thursday. The company has a fifty day simple moving average of $121.45 and a 200 day simple moving average of $113.89. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17. The company has a market cap of $7.27 billion, a P/E ratio of 16.93, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on JAZZ. Piper Sandler reaffirmed an “overweight” rating and issued a $163.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $140.00 to $175.00 in a report on Thursday, December 12th. Robert W. Baird upped their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research note on Monday, November 18th. Finally, TD Cowen decreased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $177.00.

Institutional Trading of Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Commonwealth Equity Services LLC grew its stake in Jazz Pharmaceuticals by 2.8% in the second quarter. Commonwealth Equity Services LLC now owns 13,522 shares of the specialty pharmaceutical company’s stock valued at $1,443,000 after purchasing an additional 364 shares in the last quarter. Natixis Advisors LLC grew its stake in shares of Jazz Pharmaceuticals by 10.7% in the second quarter. Natixis Advisors LLC now owns 21,231 shares of the specialty pharmaceutical company’s stock valued at $2,266,000 after buying an additional 2,054 shares in the last quarter. Victory Capital Management Inc. increased its holdings in Jazz Pharmaceuticals by 42.7% during the second quarter. Victory Capital Management Inc. now owns 205,492 shares of the specialty pharmaceutical company’s stock worth $21,932,000 after buying an additional 61,458 shares during the last quarter. Arizona State Retirement System lifted its stake in Jazz Pharmaceuticals by 0.8% in the second quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock valued at $1,770,000 after acquiring an additional 130 shares during the last quarter. Finally, Foundry Partners LLC acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $323,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.